[go: up one dir, main page]

AR086876A1 - Derivados heterociclicos de sulfonamida - Google Patents

Derivados heterociclicos de sulfonamida

Info

Publication number
AR086876A1
AR086876A1 ARP120102040A ARP120102040A AR086876A1 AR 086876 A1 AR086876 A1 AR 086876A1 AR P120102040 A ARP120102040 A AR P120102040A AR P120102040 A ARP120102040 A AR P120102040A AR 086876 A1 AR086876 A1 AR 086876A1
Authority
AR
Argentina
Prior art keywords
sulfonamide
heterociclic
derivatives
compounds
heterociclic derivatives
Prior art date
Application number
ARP120102040A
Other languages
English (en)
Inventor
Ramulu Poddutoori
Can Wang
Xianglin Zhao
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of AR086876A1 publication Critical patent/AR086876A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Psychiatry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

Compuestos; composición farmacéutica y proceso de preparación de compuesto de fórmula (1) y (2), y sales farmacéuticamente aceptables de los mismos. Los compuestos se han demostrado como inhibidores de MEK y por lo tanto pueden ser útiles en el tratamiento de enfermedades hiperproliferativas como el cáncer y la inflamación.
ARP120102040A 2011-06-09 2012-06-08 Derivados heterociclicos de sulfonamida AR086876A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN1634DE2011 2011-06-09

Publications (1)

Publication Number Publication Date
AR086876A1 true AR086876A1 (es) 2014-01-29

Family

ID=47293670

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP120102040A AR086876A1 (es) 2011-06-09 2012-06-08 Derivados heterociclicos de sulfonamida

Country Status (5)

Country Link
US (1) US8470878B2 (es)
CN (1) CN103748085A (es)
AR (1) AR086876A1 (es)
TW (1) TW201302721A (es)
UY (1) UY34121A (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105384754B (zh) * 2014-09-02 2018-04-20 上海科州药物研发有限公司 作为蛋白激酶抑制剂的杂环类化合物及其制备方法和用途
WO2017033113A1 (en) 2015-08-21 2017-03-02 Acerta Pharma B.V. Therapeutic combinations of a mek inhibitor and a btk inhibitor
US11806321B2 (en) * 2022-03-17 2023-11-07 Springworks Therapeutics, Inc. Non-linear dosing of mirdametinib

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004524289A (ja) 2000-12-22 2004-08-12 アストラゼネカ・アクチエボラーグ 治療化合物
JPWO2002100833A1 (ja) 2001-06-12 2004-09-24 住友製薬株式会社 Ｒｈｏキナーゼ阻害剤
EP1478631A1 (en) 2001-11-28 2004-11-24 AstraZeneca AB Therapeutic compounds
SI1637527T1 (sl) 2003-06-26 2013-07-31 Takeda Pharmaceutical Company Limited Modulator kanabinoidnega receptorja
GB0420719D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
SI1986633T1 (sl) 2006-02-10 2015-03-31 Summit Corporation Plc Zdravljenje Duchennove mišične distrofije
JP5491199B2 (ja) * 2007-01-19 2014-05-14 アルデア バイオサイエンシズ，インコーポレイティド Ｍｅｋのインヒビター
UA99731C2 (ru) 2007-07-30 2012-09-25 Ардеа Биосайенсис, Инк Кристаллические полиморфные формы n-(ариламино)сульфонамидов как ингибиторы мэк, композиция (варианты) и применение
BRPI0811317A2 (pt) 2007-08-03 2015-01-27 Summit Corp Plc Combinação, embalagem farmcêutica, kit ou mbalagem par apaciente, agente auxiliar, compsoto, usos de um agente auxiliar e de um composto, e, processo para a produção de uma combinação
US20110098288A1 (en) 2008-03-11 2011-04-28 Jeremy Major Sulfonamides as zap-70 inhibitors
CN102134218A (zh) 2009-06-15 2011-07-27 凯美隆(北京)药业技术有限公司 6-芳氨基吡啶酮磺酰胺和6-芳氨基吡嗪酮磺酰胺mek抑制剂
ES2484171T3 (es) * 2009-12-08 2014-08-11 Novartis Ag Derivados de sulfonamidas heterocíclicas

Also Published As

Publication number Publication date
TW201302721A (zh) 2013-01-16
CN103748085A (zh) 2014-04-23
US8470878B2 (en) 2013-06-25
UY34121A (es) 2013-01-31
US20120316149A1 (en) 2012-12-13

Similar Documents

Publication Publication Date Title
CY1119490T1 (el) Παραγωγα πυραζολοπυρρολιδινης και η χρηση τους στην θεραπεια νοσηματων
CY1118379T1 (el) Αναστολεις ιου ηπατιτιδας c
MX345928B (es) Composiciones terapeuticamente activas y metodos de uso de las mismas.
DOP2014000152A (es) Inhibidores de bromodominios
UY33183A (es) Compuestos inhibidores de virus flaviviridae, composición farmaceutica que los contiene y su uso en la manufactura de un medicamento
EA201592256A1 (ru) Производные имидазопирролидинона и их применение при лечении заболеваний
UY32158A (es) Derivados heterociclicos y metodos de uso de los mismos
MX2014012695A (es) Derivados de isoindolona.
EA201490471A1 (ru) Пиридазиноновые соединения и их применение в качестве ингибиторов daao
CO6491060A2 (es) Compuestos y composiciones para el tratamiento de enfermedades parasitarias
UA113215C2 (xx) Похідні проліків (e)-n-метил-n-((3-метилбензофуран-2-іл)метил)-3-(7-оксо-5,6,7,8-тетрагідро-1,8-нафтиридин-3-іл)акриламіду
MX2015016425A (es) Derivados de pirazolo-pirrolidin-4-ona y su uso en el tratamiento de enfermedades.
EA201600434A1 (ru) Применение производных бензимидазолпролина
CY1120133T1 (el) Πυριδαζινονες ως αναστολεις ενζυμου daao
UY32674A (es) Derivados heterociclicos de la urea y sus metodos de empleo
JOP20190086A1 (ar) مشتقات نافثيريدينون جديدة واستخدامها في معالجة عدم انتظام ضربات القلب
UY32856A (es) Derivados heterocíclicos de urea y métodos de uso de los mismos
UY32694A (es) Derivados heterocíclicos de urea y métodos de uso de los mismos
ECSP12011984A (es) Derivados de sulfonamida heterocíclicos
EA201490573A1 (ru) Соединение бензотиазолона
EA201391820A1 (ru) Гетероциклические сульфонамидные производные
AR086876A1 (es) Derivados heterociclicos de sulfonamida
UY33806A (es) ?compuestos novedosos de imidazoquinolina, composiciones que los contienen y su uso en el tratamiento de enfermedades mediadas por tlr7?
CU20100005A7 (es) Derivados de pirimidina trisustituida para el tratamiento de enfermedades proliferativas
CU20100172A7 (es) Derivados heterocíclicos de urea y métodos de uso de los mismos-211

Legal Events

Date Code Title Description
FA Abandonment or withdrawal